Skip to main content
Header image

Non-invasive lung cancer diagnostics using proteomic biomarkers in exhaled breath condensate

Project acronym: NV16-32318A
Project title: Non-invasive lung cancer diagnostics using proteomic biomarkers in exhaled breath condensate
Project registration number: NV16-32318A
State funding provider: The Ministry of Health
Programme: NV - Programme for the Support of Applied Medical Research for the years 2015 - 2023 (2015 - 2023)
Start date: 2016-04-01
End date: 2019-12-31
Principal investigator: Hajdúch Marián M.D., Ph.D.

Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases. Finding non-invasive methods for early detection of lung cancer on the background of underlying lung injury (inflammation, smoking, infections, etc.) would be highly beneficial. Proteomic analysis of EBC has the potential to detect early changes in the status of the respiratory system and possibly other organs. It could also replace or complement some invasive sampling methods in future and provide non-invasive lung cancer screening technique. Together, our studies will advance the development and validation of EBC as a novel tool for the proper diagnosis of lung cancer and monitoring of disease activity, treatment efficacy and prognosis.